| Flucelvax, Flucelvax Quadrivalent |
125408 |
003 |
351(a) |
Influenza Vaccine |
Injection |
Intramuscular |
60UG/.5ML |
Multi-Dose Vial |
2017/03/03
|
Seqirus Inc. |
Disc |
Licensed |
N/A |
N/A |
| hudquzco rubber panel,rubber panel t.r.u.e. test |
125579 |
001 |
351(a) |
Rubber Panel Thin-Layer Rapid Use Epicutaneous Patch Test |
Patch |
Topical |
PATCH TEST 5 ALLERGEN AND ALLERGEN MIX PATCHES AND A NEGATIVE CONTROL. |
Blister Pack |
2017/03/03
|
SmartPractice Denmark ApS |
Rx |
Licensed |
|
N/A |
| Odactra |
125592 |
001 |
351(a) |
House Dust Mites (Dermatophagoides farinae and Dermatophagoides pteronyssinus) Allergen Extract |
Tablet |
Sublingual |
12 SQ-HDM/ML |
Blister Pack |
2017/03/01
|
ALK - Abello A/S |
Rx |
Licensed |
|
N/A |
| Jetrea |
125422 |
001 |
351(a) |
ocriplasmin |
Injection |
Intravitreal |
0.375MG/0.3ML (1.25MG/ML) |
Single-Dose Vial |
2017/02/22
|
ThromboGenics Inc. |
Disc |
Voluntarily Revoked |
N/A |
N/A |
| Siliq |
761032 |
001 |
351(a) |
brodalumab |
Injection |
Subcutaneous |
210MG/1.5ML |
Pre-Filled Syringe |
2017/02/15
|
Bausch Health Ireland, Limited |
Rx |
Licensed |
N/A |
N/A |
| Herceptin |
103792 |
002 |
351(a) |
trastuzumab |
For Injection |
Intravenous |
150MG |
Single-Dose Vial |
2017/02/10
|
Genentech, Inc. |
Rx |
Licensed |
N/A |
N/A |
| Gammaplex |
125329 |
005 |
351(a) |
Immune Globulin Intravenous (Human) |
Injection |
Intravenous |
5G/50ML |
Single-Dose Vial |
2017/02/06
|
Bio Products Laboratory Limited |
Rx |
Licensed |
|
N/A |
| Gammaplex |
125329 |
006 |
351(a) |
Immune Globulin Intravenous (Human) |
Injection |
Intravenous |
10G/100ML |
Single-Dose Vial |
2017/02/06
|
Bio Products Laboratory Limited |
Rx |
Licensed |
|
N/A |
| Gammaplex |
125329 |
007 |
351(a) |
Immune Globulin Intravenous (Human) |
Injection |
Intravenous |
20G/200ML |
Single-Dose Vial |
2017/02/06
|
Bio Products Laboratory Limited |
Rx |
Licensed |
|
N/A |
| Eloctate |
125487 |
008 |
351(a) |
Antihemophilic Factor (Recombinant), Fc Fusion protein |
For Injection |
Intravenous |
5000IU |
Single-Dose Vial |
2017/01/27
|
Bioverativ Therapeutics, Inc. |
Rx |
Licensed |
|
N/A |
| Eloctate |
125487 |
009 |
351(a) |
Antihemophilic Factor (Recombinant), Fc Fusion protein |
For Injection |
Intravenous |
6000IU |
Single-Dose Vial |
2017/01/27
|
Bioverativ Therapeutics, Inc. |
Rx |
Licensed |
|
N/A |
| Eloctate |
125487 |
010 |
351(a) |
Antihemophilic Factor (Recombinant), Fc Fusion protein |
For Injection |
Intravenous |
4000IU |
Single-Dose Vial |
2017/01/27
|
Bioverativ Therapeutics, Inc. |
Rx |
Licensed |
|
N/A |
| Ilaris |
125319 |
002 |
351(a) |
canakinumab |
Injection |
Subcutaneous |
150MG/ML |
Single-Dose Vial |
2016/12/22
|
Novartis Pharmaceuticals Corporation |
Rx |
Licensed |
N/A |
N/A |
| Maci |
125603 |
001 |
351(a) |
autologous cultured chondrocytes on porcine collagen membrane |
Cell Sheets |
Implantation |
500,000 CM2 CM2 |
Pouch |
2016/12/13
|
Vericel Corporation |
Rx |
Licensed |
|
N/A |
| Xultophy 100/3.6 |
208583 |
001 |
351(a) |
insulin degludec and liraglutide |
Injection |
Subcutaneous |
300UNITS/3ML (100UNITS/ML); 10.8MG/3ML (3.6MG/ML) |
Autoinjector |
2016/11/21
|
Novo Nordisk Inc. |
Rx |
Licensed |
N/A |
N/A |
| Soliqua 100/33 |
208673 |
001 |
351(a) |
insulin glargine and lixisenatide |
Injection |
Subcutaneous |
300UNITS/3ML (100UNITS/ML); 99MCG/3ML (33MCG/ML) |
Autoinjector |
2016/11/21
|
Sanofi-Aventis U.S. LLC |
Rx |
Licensed |
N/A |
N/A |
| Adynovate |
125566 |
005 |
351(a) |
Antihemophilic Factor (Recombinant), PEGylated |
For Injection |
Intravenous |
1500IU |
Single-Dose Vial |
2016/10/25
|
Takeda Pharmaceuticals U.S.A., Inc. |
Rx |
Licensed |
|
N/A |
| Adynovate |
125566 |
006 |
351(a) |
Antihemophilic Factor (Recombinant), PEGylated |
For Injection |
Intravenous |
750IU |
Single-Dose Vial |
2016/10/25
|
Takeda Pharmaceuticals U.S.A., Inc. |
Rx |
Licensed |
|
N/A |
| Zinplava |
761046 |
001 |
351(a) |
bezlotoxumab |
Injection |
Intravenous |
1,000MG/40ML (25MG/ML) |
Single-Dose Vial |
2016/10/21
|
Merck Sharp & Dohme LLC |
Rx |
Licensed |
N/A |
N/A |
| Lartruvo |
761038 |
001 |
351(a) |
olaratumab |
Injection |
Intravenous |
500MG/50ML (10MG/ML) |
Single-Dose Vial |
2016/10/19
|
Eli Lilly and Company |
Disc |
Voluntarily Revoked |
N/A |
N/A |